Micro Laboratories Acquires St. John's Wort Spray.

Business Editors

JOHNSTON, R.I.--(BUSINESS WIRE)--May 11, 2000

Micro Laboratories, Inc., (OTCBB:MLAR), announced today that it has acquired the rights to manufacture St. John's Wort in its revolutionary Micro Spray(R) delivery format. St. John's Wort is the fastest rising star in herbal medicine. In fact, according to a recently published article by Dr. Michael T. Murray, St. John's Wort has been proven to produce equal or better results in relieving depression, but with far fewer side effects than many frequently prescribed drugs such as Prozac. This highly effective and safe herb is now available in the most convenient form, Micro Spray(R). Sprayed under the tongue or inside the cheek, the benefits of the herb are absorbed instantly and directly into the blood stream, thus bypassing the gastrointestinal tract and eliminating the need to swallow bulky pills.

Robert Thistle, CEO of Micro Laboratories, stated that "Anti-depressant drugs such as Prozac, Paxil and Zoloft are some of the leading prescribed pharmaceuticals in the multibillion dollar pharmaceutical industry. St. John's Wort in Micro Spray(R) form will be a welcome alternative for many patients, because St. John's Wort does not have the negative side effects associated with existing prescribed antidepressants. This one product alone should bring millions of dollars of sales annually to Micro Laboratories, Inc. and solidify its fore` into the biotech arena."

As previously announced in January of this year, Granard Pharmaceutical recently signed a three-year contract with Micro Laboratories for the sales and marketing of their propriety line of oral spay vitamin and herbal products. Granard is currently pursuing retail-marketing channels for the Micro Spray(R) line. "With the addition of St. John's Wort to Micro Laboratories other exciting line of vitamin products, Micro Spray(R) with it's unique and superior delivery system has positioned itself to become a leader within the vitamin category," stated Matt Regan, Vice President of Sales for Granard Pharmaceutical.

For more information call 800/555-1276. Micro Laboratories, Inc. is a publicly held company that trades under the stock symbol MLAR.

Safe Harbor Statement

Statements about the company's future expectations, including future revenues, earnings and transactions, as well as all other statements in the news release other than historical facts are "forward-looking statement" within the meaning of the Private Securities Litigation Reform Act of 1995. The company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results and other corporate developments could differ materially from that which has been anticipated in such statements.